Who are Sotagliflozin High Dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RT001, Semaglutide, Empagliflozin, Dapagliflozin/Pioglitazone, Bexagliflozin tablets, Keverprazan 10 days, Insulin/Empaglifozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sotagliflozin-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sotagliflozin High Dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sotagliflozin High Dose (Sotagliflozin High Dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT1 and SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Sotagliflozin High Dose (Sotagliflozin High Dose) — University of California, San Diego. Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, which helps to reduce glucose reabsorption in the kidneys and intestines.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sotagliflozin High Dose TARGET	Sotagliflozin High Dose	University of California, San Diego	phase 3	SGLT2 inhibitor	SGLT1 and SGLT2
RT001	RT001	Biojiva LLC	phase 3	SGLT1 and SGLT2 inhibitor	SGLT1 and SGLT2
Semaglutide, Empagliflozin	Semaglutide, Empagliflozin	University Medical Center, Kazakhstan	marketed	GLP-1 receptor agonist + SGLT2 inhibitor combination	GLP-1 receptor; SGLT2
Dapagliflozin/Pioglitazone	Dapagliflozin/Pioglitazone	Boryung Pharmaceutical Co., Ltd	marketed	SGLT2 inhibitor / Thiazolidinedione combination	SGLT2 / PPAR-γ
Bexagliflozin tablets	Bexagliflozin tablets	Theracos	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Keverprazan 10 days	Keverprazan 10 days	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	SGLT2 inhibitor	SGLT2
Insulin/Empaglifozin	Insulin/Empaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sotagliflozin High Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/sotagliflozin-high-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab